Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Mercaptopurine Anhydrous. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PI4KA | P42356 | 2/20 | 0.32 |
| ▸ | PI4K2B | Q8TCG2 | 2/20 | 0.32 |
| ▸ | PI4K2A | Q9BTU6 | 2/20 | 0.32 |
| ▸ | PI4KB | Q9UBF8 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | DRD3 | P35462 | 1/20 | 0.32 |
| ▸ | XDH | P47989 | 1/20 | 0.32 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.32 |
| ▸ | CSNK2A2 | P19784 | 2/20 | 0.30 |
| ▸ | CSNK2A1 | P68400 | 2/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.30 |
| ▸ | HBB | P68871 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Mercaptopurine Anhydrous SCHEMBL8843 | 0.98 | PI4KA (0.33) | PI4KAPI4K2BPI4K2API4KBLMNA | |
| Mercaptopurine Anhydrous SCHEMBL734087 | 0.96 | PI4KA (0.32) | PI4KAPI4K2BPI4K2API4KBLMNA | |
| Mercaptopurine Anhydrous SCHEMBL7199288 | 0.82 | — | — | |
| Mercaptopurine Anhydrous SCHEMBL12476114 | 0.81 | ALDH1A1 (0.62) | PI4KAPI4K2BPI4K2API4KBLMNA | |
| Mercaptopurine Anhydrous SCHEMBL18317326 | 0.75 | LMNA (0.51) | LMNAALDH1A1HBBSMN1; SMN2 | |
| Adenine SCHEMBL4887728 | 0.74 | PI4KA (0.45) | PI4KAPI4K2BPI4K2API4KBLMNA | |
| Adenine SCHEMBL3413247 | 0.73 | PI4KA (0.48) | PI4KAPI4K2BPI4K2API4KBLMNA | |
| Adenine SCHEMBL8110 | 0.73 | PI4KA (0.48) | PI4KAPI4K2BPI4K2API4KBLMNA | |
| SCHEMBL10285464 | 0.73 | PI4KA (0.34) | PI4KAPI4K2BPI4K2API4KBLMNA | |
| Adenine SCHEMBL3416954 | 0.73 | PI4KA (0.48) | PI4KAPI4K2BPI4K2API4KBLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1043975-A4 | MAGNETICALLY RESPONSIVE COMPOSITION | FERX INC (US) | 2007-05-02 | — | — | EP | disclosed |
| US-20030108614-A1 | Magnetically responsive composition | FERX INCORPORATED, A COLORADO CORPORATION | 2003-06-12 | — | — | US | disclosed |
| US-6482436-B1 | ANTITUMOR | FERX INCORPORATED | 2002-11-19 | — | — | US | disclosed |
| US-6200547-B1 | CARRIER INCLUDING PARTICLES THAT INCLUDE IRON AND CARBON; THERAPEUTIC AMOUNT OF DOXORUBICIN OR PACLITAXEL ADSORBED ON THE PARTICLES. | FERX INCORPORATED | 2001-03-13 | — | — | US | disclosed |
| EP-1043975-A1 | MAGNETICALLY RESPONSIVE COMPOSITION | Ferx Incorporated (US) | 2000-10-18 | — | — | EP | disclosed |
| WO-1999034779-A1 | MAGNETICALLY RESPONSIVE COMPOSITION | FERX INCORPORATED (US) | 1999-07-15 | — | — | WO | disclosed |
| EP-0120907-A1 | PHARMACEUTICAL PREPARATIONS FOR USE IN ANTITUMOUR THERAPY | Aston Molecules Limited (GB) | 1984-10-10 | — | — | EP | disclosed |
| WO-1984001506-A1 | PHARMACEUTICAL PREPARATIONS FOR USE IN ANTITUMOUR THERAPY | UNIV BIRMINGHAM (GB) | 1984-04-26 | — | — | WO | disclosed |